Showing 1189 results
- Media Release /Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an…
- Key Release /Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
- Media Release /First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
- Media Release /Novartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
- Key Release /Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…
- Key Release /Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
- Media Release /
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a… - Media Release /Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia Novartis global CAR-T manufacturing footprint now…
- Media Release /Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than…
- Media Release /Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.Novartis gains two pre-clinical optogenetic AAV gene therapy…
Pagination
- ‹ Previous page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- …
- 119
- › Next page